The Effect of Highly Active Antiretroviral Therapy for HIV on the Anti-HCV Specific Humoral Immune Response

Journal of Medical Virology

Volumn 72, Issue 2, 2004, Pages 187-193

  Herrero Martínez, Esteban ^a,b   Sabin, Caroline A ^a   Lee, Christine A ^b   Jones, Ian M ^c   Pillay, Deenan ^d   Emery, Vincent C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF READING   (United Kingdom)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Antiretroviral therapy; Hepatitis; Immunoglobulin

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS C ANTIBODY; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS GLYCOPROTEIN; VIRUS RNA;

ANTIBODY RESPONSE; ARTICLE; BLEEDING DISORDER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MALE; VIRUS ENVELOPE; VIRUS REPLICATION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELLS, CULTURED; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; SPODOPTERA; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL STRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 0347064340     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10578     Document Type: Article

References (51)

1. Agrati C, D'Offizi G, Narciso P, Selva C, Pucillo LP, Ippolito G, Poccia F. 2001. Gammadelta T cell activation by chronic HIV infection may contribute to intrahepatic vdeltal compartmentalization and hepatitis C virus disease progression independent of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 17:1357-1363.
2. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M, Zauli D, Alberti A, Bianchi FB. 1995. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 95:2067-2075.
3. Baumert TF, Wellnitz S, Aono S, Satoi J, Herion D, Tilman Gerlach J, Pape GR, Lau JY, Hoofnagle JH, Blum HE, Liang TJ. 2000. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology 32:610-617.
4. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, Curran JW. 1992. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41:1-19.
5. Chan-Fook C, Jiang WR, Clarke BE, Zitzmann N, Maidens C, McKeating JA, Jones IM. 2000. Hepatitis C virus glycoprotein E2 binding to CD81: The role of E1E2 cleavage and protein glycosylation in bioactivity. Virology 273:60-66.
6. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, McHutchison JG, Alter HJ, Chisari FV. 2001. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33:267-276.
7. Curran R, Jameson CL, Craggs JK, Grabowska AM, Thomson BJ, Robins A, Irving WL, Ball JK. 2002. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 83:11-23.
8. Darby SC, Ewart DW, Giangrande PL, Dolin PJ, Spooner RJ, Rizza CR. 1995. Mortality before and after HIV infection in the complete UK population of haemophiliacs. UK Haemophilia Centre Directors' Organisation. Nature 377:79-82.
9. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. 2000. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14:2895-2902.
10. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR. 1995. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006-1007.
11. Eckels DD, Wang H, Bian TH, Tabatabai N, Gill JC. 2000. Immunobiology of hepatitis C virus (HCV) infection: The role of CD4 T cells in HCV infection. Immunol Rev 174:90-97.
12. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan SC, Goedert JJ. 1993. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 6:602-610.
13. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. 2000. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344.
14. Fialaire P, Payan C, Vitour D, Chennebault JM, Loison J, Pichard E, Lunel F. 1999. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 180:574-575.
15. Garcia-Samaniego J, Bravo R, Castilla J, Gomez-Cano M, Laguna F, Munoz F, Soriano V. 1998. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. J Hepatol 28:526-527.
16. Gerlach JT, Diepolder HM, Jung MC, et al. 1999. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117:933-941.
17. Ginsburg C, Salmon-Ceron D, Vassilief D, Rabian C, Rotschild C, Fontenay-Roupie M, Stieltjes N, Sicard D. 1997. Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS 11:388-389.
18. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829.
19. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Jr., Feinberg JE, Balfour HH, Jr., Deyton LR, Chodakewitz JA, Fischl MA. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337:725-733.
20. Harcourt G, Hellier S, Bunce M, Satsangi J, Collier J, Chapman R, Phillips R, Klenerman P. 2001. Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat 8:174-179.
21. Hendricks DA, Freisenhahn M, Tanimoto L, Goergen B, Dodge D, Comanor L. 2003. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for the detection of hepatitis C virus RNA. J Clin Microbiol 41:651-656.
22. Herrero-Martinez E, Devereux HL, Sabin CA, Bishop JA, Lee CA, Emery VC. 2000. Development of a quantitative competitive RT-PCR assay for hepatitis C virus. Antivir Ther 5(suppl 1): C.3.
23. Herrero-Martinez E, Sabin CA, Evans JG, Griffioen A, Lee CA, Emery VC. 2002. The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion. J Infect Dis 186:470-476.
24. Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, Aizaki H, Matsuura Y, Houghton M, Abrignani S, Miyamura T. 1998. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28:1117-1120.
25. Klenerman P, Lechner F, Kantzanou M, Ciurea A, Hengartner H, Zinkernagel R. 2000. Viral escape and the failure of cellular immune responses. Science 289:2003.
26. Klenerman P, Lucas M, Barnes E, Harcourt G. 2002. Immunity to hepatitis C virus: Stunned but not defeated. Microbes Infect 4:57-65.
27. Kondili LA, Chionne P, Costantino A, et al. 2002. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 50:693-696.
28. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. 2000a. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191:1499-1512.
29. Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, Cerny A, Phillips R, Ferrari C, Pape GR, Klenerman P. 2000b. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30:2479-2487.
30. Lee CA, Phillips A, Elford J, Miller EJ, Bofill M, Griffiths PD, Kernoff PB. 1989. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol 73:228-234.
31. Lipsky JJ. 1996. Antiretroviral drugs for AIDS. Lancet 348:800-803.
32. Matsiota-Bernard P, Vrioni G, Onody C, Bernard L, de Truchis P, Peronne C. 2001. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. Int J Antimicrob Agents 17:155-157.
33. Moore JP, McKeating JA, Jones IM, Stephens PE, Clements G, Thomson S, Weiss RA. 1990. Characterization of recombinant gp120 and gp160 from HIV-1: Binding to monoclonal antibodies and soluble CD4. AIDS 4:307-315.
34. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. 1996. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24:759-765.
35. Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. 1997. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol 27:30-35.
36. Perez-Olmeda M, Garcia-Samaniego J, Soriano V. 2000. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 14:212.
37. Ragni MV, Bontempo FA. 1999. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 180:2027-2029.
38. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. 1999. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30:787-793.
39. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, Rabkin J, Corless CL, Bouwer HG. 1999. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 117:926-932.
40. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. 1998. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 177:783-785.
41. Sabin CA, Yee TT, Devereux H, Griffioen A, Loveday C, Phillips AN, Lee CA. 2000. Two decades of HIV infection in a cohort of haemophilic individuals: Clinical outcomes and response to highly active antiretroviral therapy. AIDS 14:1001-1007.
42. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L. 2001. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 33:455-463.
43. Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. 1994. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 46:504-511.
44. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. 2000. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80.
45. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578-582.
46. Tseng CT, Klimpel GR. 2002. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 195:43-49.
47. Valdez H, Anthony D, Farukhi F, Patki A, Salkowitz J, Heeger P, Peterson DL, Post AB, Asaad R, Lederman MM. 2000. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 14:2239-2246.
48. Yee TT, Amrolia PJ, Lee CA, Mir N, Giangrande PL. 1997. Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 3:219-221.
49. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. 2000. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 47:845-851.
50. Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y. 2000. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: Influence of antiretroviral therapy. Blood 9:4293-4299.
51. Zylberberg H, Pol S. 1998. Characteristics and treatment of hepatitis C virus infection in HIV-coinfected subjects. AIDS Patient Care STDS 12:11-19.